VYNE Therapeutics Inc. (VYNE) Social Stream

VYNE Therapeutics Inc. (VYNE): $0.64

-0.02 (-2.41%)

POWR Rating

Component Grades













Add VYNE to Watchlist
Sign Up

Industry: Biotech


of 461

in industry

VYNE Therapeutics Inc (VYNE) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering VYNE Therapeutics Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
6 $14 $3 $7.166 $1.04 589.04%
6 $14 $3 $6.666 $1.04 540.96%
6 $14 $3 $6.5 $1.04 525%
6 $14 $3 $7.2 $1.04 592.31%

Over the past 47 weeks, VYNE's average upside potential has been 251.07%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-12-06 6 14 3 7.166 1.20 497.17%
2021-06-13 0 15 8 11.430 3.99 186.47%
2021-01-09 NA 10 3 5.690 NA NA%

VYNE Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 6 0 0 0 0 6

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In terms of how VYNE Therapeutics Inc fares relative to all US stocks, note that its variance in analysts' estimates is lower than -296.32% of that group.
  • VYNE has a greater upside potential (average analyst target price relative to current price) than 391.82% of all US stocks.
  • To contextualize these metrics, consider that out of Healthcare stocks, VYNE Therapeutics Inc's average analyst price target is higher than 43.6% of them.
  • VYNE has a higher number of analysts covering the stock than 317.6% of stocks in the small market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to VYNE Therapeutics Inc are CLRB, BDTX and MNPR.

Is VYNE a Buy, Hold or Sell? See the POWR Ratings now!

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7024 seconds.